Bulking agents have been used for decades as an alternative treatment for patients with stress urinary incontinence who are not appropriate for surgery. Despite this their long-term complications are poorly documented and can be misdiagnosed. This paper presents a literature review and the results of a national survey of members of the Section of Female, Neurological and Urodynamic Urology (FNUU) of the British Association of Urological Surgeons (BAUS) identifying the common long-term complications of widely used bulking agents in clinical practice.
Methods:
Following a comprehensive literature review an electronic survey was sent to members of the BAUS Section of FNUU. Data included hospital trust, use of urethral bulking agents (including type), the approximate number of procedures performed and whether any long-term complications had been observed and managed in their practice. Long-term complications were defined as those arising more than 12 months after treatment.
Results:
The literature review revealed multiple case reports of complications secondary to bulking agent injection but no high-level evidence regarding frequency or severity. The survey revealed complications including granulomas, erosions, abscesses and misdiagnoses of urethral diverticula and calculi formation. 88% of urologists who responded to the survey had performed a urethral bulking agent injection and 51% of urologists had observed or treated a long-term complication, some many decades after injection.
Conclusion:
Patients should be made aware of possible long-term complications of what appears to be a minimally invasive procedure in order for them to make an informed choice about treatment options.
TurnerDAShawCMcGrotherCW, et al. The cost of clinically significant urinary storage symptoms for community dwelling adults in the UK. BJU Int2004; 93(9): 1246–1252, http://doi.wiley.com/10.1111/j.1464-410x.2004.04806.x (accessed 21 March 2021).
2.
McGrotherCWDonaldsonMMKShawC, et al. Storage symptoms of the bladder: Prevalence, incidence and need for services in the UK. BJU Int2004; 93(6): 763–769, http://doi.wiley.com/10.1111/j.1464-410X.2003.04721.x (accessed 21 March 2021).
Borello-FranceDFDowneyPAZyczynskiHM, et al. Continence and quality-of-life outcomes 6 months following an intensive pelvic-floor muscle exercise program for female stress urinary incontinence: A randomized trial comparing low- and high-frequency maintenance exercise. Phys Ther2008; 88(12): 1545–1553.
5.
KimAKimSKimHG. Current overview of surgical options for female stress urinary incontinence. Int Neurourol J2020; 24: 222–230.
6.
KirchinVPageTKeeganPE, et al. Urethral injection therapy for urinary incontinence in women. Cochrane Database Syst Rev, https://pubmed.ncbi.nlm.nih.gov/22336797/ (accessed 29 June 2021).
7.
HerschornS. Current use of injectable agents for female stress urinary incontinence. Rev Urol2005; 7(Suppl. 1): S12.
8.
MayerRDDmochowskiRRAppellRA, et al. Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence. Urology2007; 69(5): 876–880, https://pubmed.ncbi.nlm.nih.gov/17482925/ (accessed 15 April 2021).
9.
ZajdaJFaragF. Clinical study urolastic – a new bulking agent for the treatment of women with stress urinary incontinence: Outcome of 12 months follow up. Adv Urol2013; 2013: 724082.
10.
van UhmJIMVermeerMElzevierHW, et al. Injectable bulking agent to treat postprostatectomy urinary incontinence: A safety and effectiveness pilot study. Biomed Res Int2018; 2018: 2796967, https://pubmed.ncbi.nlm.nih.gov/30627546/ (accessed 15 April 2021).
11.
HobbsCFoleyS. PD28-01 Still dry! Longevity of Deflux urethral bulking injections for urinary stress incontinence. J Urol2015; 193: e644.
12.
SeratiMSoligoMBragaA, et al. Efficacy and safety of polydimethylsiloxane injection (Macroplastique ®) for the treatment of female stress urinary incontinence: Results of a series of 85 patients with ⩾3 years of follow-up. BJU Int2019; 123(2): 353–359, www.bjui.org (accessed 30 June 2021).
13.
PaiAAl-SingaryW. Durability, safety and efficacy of polyacrylamide hydrogel (Bulkamid®) in the management of stress and mixed urinary incontinence: Three year follow up outcomes. Cent European J Urol2015; 68(4): 428–433.
14.
SurkontGWlaźlakESuzinJ. Long-term risk of complications after mid-urethral sling IVS implantation. Ann Agric Environ Med2015; 22(1): 163–166, https://pubmed.ncbi.nlm.nih.gov/25780848/ (accessed 3 September 2021).
15.
MatsumotoFMatsuiFYazawaK, et al. [A CASE OF DEXTRANOMER-HYALURONIC ACID COPOLYMER (Deflux ®) IMPLANTS CALCIFICATION MIMICKING DISTAL URETERAL CALCULI]. Nihon Hinyokika Gakkai Zasshi2017; 108(1): 49–51, https://pubmed.ncbi.nlm.nih.gov/29367510/ (accessed 15 August 2021).
16.
KumarDKaufmanMRDmochowskiRR. Case reports: Periurethral bulking agents and presumed urethral diverticula. Int Urogynecol J2011; 22(8): 1039–1043, https://pubmed.ncbi.nlm.nih.gov/21340644/ (accessed 18 May 2021).
17.
HoeVHallerBYaoHH, et al. Urethral bulking agents for the treatment of stress urinary incontinence in women: A systematic review. Neurourol Urodyn2021; 40(6): 1349–1388.
18.
MamutACarlsonKV. Periurethral bulking agents for female stress urinary incontinence in Canada. Can Urol Assoc J2017; 11: S152–S154.
19.
KandaswamyGVRandhawaKSDhanasekaranAK. Case report. J Clin Urol2017; 10(5): 487–488.
20.
RaffeeSAtiemoH. Polydimethylsiloxane erosion as a cause for recurrent urinary tract infections. J Endourol Case Rep2019; 5(3): 117–119.
21.
SavvasCAraklitisGShahC, et al. Urethral bulking agent found in a urethral caruncle which did not respond to topical oestrogens: A case report. Case Rep Womens Health2020; 28: e00268.
22.
ZajdaJFaragF. Urolastic – a new bulking agent for the treatment of women with stress urinary incontinence: Outcome of 12 months follow up. Adv Urol2013; 2013: 724082.
23.
ZajdaJFaragF. Urolastic for the treatment of women with stress urinary incontinence: 24-month follow-up. Cent European J Urol2015; 68(3): 334–338, https://pubmed.ncbi.nlm.nih.gov/26568877/ (accessed 4 June 2021).
24.
de VriesAMvan BredaHMKFernandesJG, et al. Para-urethral injections with Urolastic® for treatment of female stress urinary incontinence: Subjective improvement and safety. Urol Int2017; 99(1): 91–97, www.karger.com/uin (accessed 4 June 2021).
25.
CasteleijnFMKowalikCRBerendsC, et al. Patients’ satisfaction and safety of bulk injection therapy Urolastic for treatment of stress urinary incontinence: A cross-sectional study. Neurourol Urodyn2020; 39(6): 1753–1763, https://pubmed.ncbi.nlm.nih.gov/32526063/ (accessed 4 June 2021).
26.
GopinathDSmithARBReidFM. Periurethral abscess following polyacrylamide hydrogel (Bulkamid®) for stress urinary incontinence. Int Urogynecol J2012; 23: 1645–1648.
27.
HagemeierTBlauUGauruder-BurmesterA, et al. [Paraurethral abscess developing after mid-urethral Zuidex-injection in women with stress urinary incontinence – management of complications and retrospective comparison with bladder neck located injection technique]. Zentralbl Gynakol2006; 128(2): 68–70, http://europepmc.org/abstract/MED/16673247
28.
OzkuvanciUIrfan DonmezMOzgorF, et al. Durasphere® EXp: A non-biodegradable agent for treatment of primary Vesico-Ureteral reflux in children. Int Braz J Urol2018; 44: 585–590.
29.
GanzRAFallonEWittchowT, et al. A new injectable agent for the treatment of GERD: Results of the Durasphere pilot trial. Gastrointest Endosc2009; 69(2): 318–323.
30.
PannekJBrandsFHSengeT. Particle migration after transurethral injection of carbon coated beads for stress urinary incontinence. J Urol2001; 166(4): 1350–1353.
31.
MadjarSSharmaAKWaltzerWC, et al. Periurethral mass formations following bulking agent injection for the treatment of urinary incontinence. J Urol2006; 175(4): 1408–1410.
32.
LaiHHHurtadoEAAppellRA. Large urethral prolapse formation after calcium hydroxylapatite (Coaptite) injection. Int Urogynecol J Pelvic Floor Dysfunct2008; 19(9): 1315–1317, https://pubmed.ncbi.nlm.nih.gov/18414766/ (accessed 12 August 2021).
33.
PalmaPCRiccettoCLMartinsMH, et al. Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct2006; 17(6): 670–671, https://pubmed.ncbi.nlm.nih.gov/16341621/ (accessed 12 August 2021).
34.
SpencerEBaberJFerrettiM. Distal ureteral calculus or deflux calcification?J Endourol Case Rep2019; 5(4): 178–180.
35.
PolcariAJKimDYHelfandBT, et al. Pseudodistal ureteral stone resulting from calcified Deflux implantation. Urology2009; 74(4): 906–907, https://pubmed.ncbi.nlm.nih.gov/19616832/ (accessed 15 August 2021).
36.
AbdelwahabHAGhoniemGM. Obstructive suburethral mass after transurethral injection of dextranomer/hyaluronic acid copolymer. Int Urogynecol J Pelvic Floor Dysfunct2007; 18: 1379–1380.
ElzayatEACorcosJ. Urethral injectables in the management of stress urinary incontinence. In: RazSRodríguezLV (eds) Female urology. Amsterdam: Elsevier, 2008, pp. 348–361.
